XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9
Acquisition - Additional Information (Detail) (USD $)
9 Months Ended 0 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Feb. 28, 2014
Feb. 27, 2015
Business Acquisition [Line Items]        
Deferred grants $ 10,447,000us-gaap_DeferredRevenueNoncurrent      
Business acquisition, cash transferred 20,115,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired 223,531,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired    
Crescendo Biosciences, Inc.        
Business Acquisition [Line Items]        
Total consideration transferred     258,950,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Business acquisition, cash transferred     225,100,000us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Elimination of intercompany balances related to accrued interest and term loan     25,900,000mygn_BusinessCombinationConsiderationTransferredEliminationOfIntercompanyBalancesRelatedToAccruedInterestAndTermLoan
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Fair value of purchase option granted     8,000,000mygn_BusinessCombinationConsiderationTransferredFairValuePurchaseOption
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Business acquisition, amount deposited into escrow account     20,000,000mygn_BusinessAcquisitionConsiderationCashDepositedEscrowAccount
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Share-based compensation to Crescendo employees     6,929,000mygn_BusinessCombinationConsiderationTransferredSharebasedCompensation
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Control bonuses paid to Crescendo employees     5,695,000mygn_BusinessCombinationConsiderationTransferredChangeOfControlPayments
/ us-gaap_BusinessAcquisitionAxis
= mygn_CrescendoBioscienceIncMember
 
Crescendo Biosciences, Inc. | Minimum        
Business Acquisition [Line Items]        
Period of audit completion     12 months  
Crescendo Biosciences, Inc. | Maximum        
Business Acquisition [Line Items]        
Period of audit completion     15 months  
German Clinic [Member]        
Business Acquisition [Line Items]        
Total consideration transferred       20,100,000us-gaap_BusinessCombinationConsiderationTransferred1
/ us-gaap_BusinessAcquisitionAxis
= mygn_GermanClinicMember
Intangible asset amortization period for income tax purposes 15 years      
Deferred grants $ 10,400,000us-gaap_DeferredRevenueNoncurrent
/ us-gaap_BusinessAcquisitionAxis
= mygn_GermanClinicMember